Tetraphase Pharma (TTPH) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tetraphase Pharmaceuticals (TTPH) PT Raised to $7 at Stifel Following 4Q Report
March 9, 2017 9:26 AM ESTStifel raised its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $7.00 (from $5.00) while maintaining a Hold rating. TTPH reported a net loss of $20M, or $(0.61)/share, wider than the Consensus of $(0.55).
Analyst Stephen Willey commented, "We continue to find TTPH shares... More
